Baculovirus Display of Varicella–Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice

Xue, Wenhui; Li, Tingting; Zhang, Sibo; Wang, Yingbin; Hong, Minqing; Cui, Liping; Wang, Hong; Zhang, Yuyun; Chen, Tingting; Zhu, Rui; Chen, Zhenqin; Zhou, Lizhi; Zhang, Rongwei; Cheng, Tong; Zheng, Qingbing; Zhang, Jun; Gu, Ying; Xia, Ningshao; Li, Shaowei

doi:10.3390/v14081785

Cited by 6 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunization with rBV displaying the rhoptry protein ROP4 protected mice from a lethal challenge with T. gondii, by inducing mucosal, cellular and humoral immunity 23 . The ability of BV-based vaccines to induce strong immune responses and protection by displaying heterologous antigens was also demonstrated for Plasmodium (PfCSP) 35 , and several viruses, including a recent work with SARS-CoV2 22,[36][37][38] . All these studies, however, were carried out displaying the heterologous antigens at BV surface.…”

Section: Discussionmentioning

confidence: 94%

Vaccine against Trypanosoma cruzi infection using the Parasite Antigen TcTASV Displayed at Baculovirus Capsid

Tekiel

Masip

Caeiro

et al. 2023

Preprint

View full text Add to dashboard Cite

Chagas' is a neglected disease caused by the eukaryotic kinetoplastid parasite Trypanosoma cruzi. Currently there are about 8 million infected people worldwide, most of them at the chronic phase of the disease, which involves cardiac, digestive or neurologic manifestations. There is an urgent need for a vaccine because treatments are only effective at the initial phase of the infection, which is generally underdiagnosed. Selection and combination of antigens, adjuvants, and delivery platforms for vaccine formulations should be designed to trigger mixed humoral and cellular immune responses, considering that T. cruzi has a complex life cycle with both intracellular and bloodstream circulating parasite stages in the vertebrate host. Here we report the effectiveness of the vaccination with a T. cruzi-specific protein family (TcTASV), employing both recombinant proteins with aluminum hydroxide and recombinant baculovirus displaying a TcTASV antigen at the capsid. Vaccination stimulated immunological responses with production of lytic antibodies and antigen-specific CD4+ and CD8+ IFNɣ secreting lymphocytes. More than 90% of vaccinated animals survived after lethal challenges with T. cruzi while all control mice died before 30 days post infection. Vaccination also induced a strong decrease of chronic tissue parasitism, and generated immunological memory that allowed vaccinated and infected animals to control both the reactivation of the infection after immunosuppression as well as a second challenge with T. cruzi. Interestingly, inoculation with wild type baculovirus trained the immune system to partially protect mice against T. cruzi. In brief, we demonstrated, for the first time, that the combination of the baculovirus platform and the TcTASV family provides effective protection against Trypanosoma cruzi, being a promising vaccine for Chagas’ disease.

show abstract

Section: Discussionmentioning

confidence: 94%

Vaccine against Trypanosoma cruzi infection using the Parasite Antigen TcTASV Displayed at Baculovirus Capsid

Tekiel

Masip

Caeiro

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Immunization with recombinant baculovirus displaying the rhoptry protein ROP4 protects mice from lethal challenge with T. gondii by inducing mucosal, cellular, and humoral immunity (Yoon et al, 2021). The ability of BV-based vaccines to induce strong immune responses and protection by displaying heterologous antigens has also been demonstrated for Plasmodium (Yoshida et al, 2018) and several viruses, including a recent work on SARS-CoV2 (Abe et al, 2003;Premanand et al, 2018;Wei et al, 2021;Xue et al, 2022). However, all of these studies have been carried out displaying heterologous antigens on the BV surface.…”

Section: Discussionmentioning

confidence: 99%

Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection

Masip,

Caeiro,

Cosenza

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Chagas’ is a neglected disease caused by the eukaryotic kinetoplastid parasite, Trypanosoma cruzi. Currently, approximately 8 million people are infected worldwide, most of whom are in the chronic phase of the disease, which involves cardiac, digestive, or neurologic manifestations. There is an urgent need for a vaccine because treatments are only effective in the initial phase of infection, which is generally underdiagnosed. The selection and combination of antigens, adjuvants, and delivery platforms for vaccine formulations should be designed to trigger mixed humoral and cellular immune responses, considering that T. cruzi has a complex life cycle with both intracellular and bloodstream circulating parasite stages in vertebrate hosts. Here, we report the effectiveness of vaccination with a T. cruzi-specific protein family (TcTASV), employing both recombinant proteins with aluminum hydroxide and a recombinant baculovirus displaying a TcTASV antigen at the capsid. Vaccination stimulated immunological responses by producing lytic antibodies and antigen-specific CD4+ and CD8+ IFNɣ secreting lymphocytes. More than 90% of vaccinated animals survived after lethal challenges with T. cruzi, whereas all control mice died before 30 days post-infection. Vaccination also induced a strong decrease in chronic tissue parasitism and generated immunological memory that allowed vaccinated and infected animals to control both the reactivation of the infection after immunosuppression and a second challenge with T. cruzi. Interestingly, inoculation with wild-type baculovirus partially protected the mice against T. cruzi. In brief, we demonstrated for the first time that the combination of the baculovirus platform and the TcTASV family provides effective protection against Trypanosoma cruzi, which is a promising vaccine for Chagas disease.

show abstract

“…Fusion of proteins to full GP64 results in chimeric proteins that possess all the signals required for transport to the membrane, maturation, and incorporation into the budded virus. Using this strategy, it has been possible to expose large proteins such as GP120 of HIV [ 44 ] and ROP4 of Toxoplasma gondii [ 45 ].…”

Section: Baculovirus-derived Immunogens For Vaccine Developmentmentioning

confidence: 99%

The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health

Pidre

Arrías

Morales

et al. 2022

Viruses

View full text Add to dashboard Cite

Baculoviruses are enveloped, insect-specific viruses with large double-stranded DNA genomes. Among all the baculovirus species, Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is the most studied. Due to its characteristics regarding biosafety, narrow host range and the availability of different platforms for modifying its genome, AcMNPV has become a powerful biotechnological tool. In this review, we will address the most widespread technological applications of baculoviruses. We will begin by summarizing their natural cycle both in larvae and in cell culture and how it can be exploited. Secondly, we will explore the different baculovirus-based protein expression systems (BEVS) and their multiple applications in the pharmaceutical and biotechnological industry. We will focus particularly on the production of vaccines, many of which are either currently commercialized or in advanced stages of development (e.g., Novavax, COVID-19 vaccine). In addition, recombinant baculoviruses can be used as efficient gene transduction and protein expression vectors in vertebrate cells (e.g., BacMam). Finally, we will extensively describe various gene therapy strategies based on baculoviruses applied to the treatment of different diseases. The main objective of this work is to provide an extensive up-to-date summary of the different biotechnological applications of baculoviruses, emphasizing the genetic modification strategies used in each field.

show abstract

Baculovirus Display of Varicella–Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice

Cited by 6 publications

References 52 publications

Vaccine against Trypanosoma cruzi infection using the Parasite Antigen TcTASV Displayed at Baculovirus Capsid

Vaccine against Trypanosoma cruzi infection using the Parasite Antigen TcTASV Displayed at Baculovirus Capsid

Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection

The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health

Contact Info

Product

Resources

About